Literature DB >> 33452541

The Development and Initial Validation of PUMC Localized Scleroderma Facial Aesthetic Index: A Pilot Study.

Hayson Chenyu Wang1, Shiqi Ling2, Xiaojun Wang3, Xiao Long4, Elliot Tianyu Sun5, Nanze Yu1, Ruijia Dong1, Ang Zeng1, Hailin Zhang1, Chang Shu6.   

Abstract

BACKGROUND: Localized scleroderma (LoS) is an autoimmune connective tissue disorder leading to serious long-term aesthetic impairment on patients. Objective evaluation methods are badly needed to facilitate the evaluation of the surgical treatment on individual patients and clinical studies.
OBJECTIVE: To develop and assess the reliability and validity of Peking Union Medical College LoS facial aesthetic index (PUMC LoSFAI).
METHODS: Twelve experts devoted their time and resources in the development and validation. LoS patients in the stable phase were recruited. Reliability and validity was then assessed. LoS patients were evaluated by two plastic surgeons using PUMC LoSFAI and LoS skin damage index (LoSDI). The PUMC LoSFAI comprises 4 domains for the local assessment (surface area of lesion, dyspigmentation, skin thickness and soft tissue atrophy) and 3 domains for the overall assessment (facial symmetry, proportion and profile) to describe LoS facial aesthetic impairment. Face-Q was completed by patients at each visit.
RESULTS: Thirty-two LoS patients had 96 visits, during which 138 lesions were assessed. PUMC LoSFAI and 7 domains demonstrated substantial to excellent inter- and intra-rater reliability (ICC 0.995, κw 0.72-0.91, r 0.85-0.99, respectively). Seven domains considered to be important to extremely important variables (mean rank 3.2-3.8) had high I-CVI (> 0.78) and S-CVI (0.93). PUMC LoSFAI correlated excellently with LoSDI (r = 0.933, P < 0.001), and correlated fairly with Face-Q (r = - 0.399, P = 0.001).
CONCLUSIONS: PUMC LoSFAI was developed and evaluated to play as a tool of aesthetic impairment assessment for LoS patients, which may facilitate the evaluation of the treatment on individual patients and clinical studies. PUMC LoSFAI demonstrated high reliability and validity, and further study in larger patient samples is needed to confirm these preliminary findings. LEVEL OF EVIDENCE IV: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine Ratings, please refer to Table of Contents or online Instructions to Authors www.springer.com/00266 .
© 2021. Springer Science+Business Media, LLC, part of Springer Nature and International Society of Aesthetic Plastic Surgery.

Entities:  

Keywords:  Aesthetic impairment; Facial aesthetic index; Localized scleroderma; Surgical outcome measure

Mesh:

Year:  2021        PMID: 33452541     DOI: 10.1007/s00266-020-02111-4

Source DB:  PubMed          Journal:  Aesthetic Plast Surg        ISSN: 0364-216X            Impact factor:   2.326


  17 in total

Review 1.  Fat Grafting for the Treatment of Scleroderma.

Authors:  Amy L Strong; J Peter Rubin; Jeffrey H Kozlow; Paul S Cederna
Journal:  Plast Reconstr Surg       Date:  2019-12       Impact factor: 4.730

2.  Localized scleroderma: a clinical study at a single center in Korea.

Authors:  Jung Won Noh; Jinseok Kim; Jae-Wang Kim
Journal:  Int J Rheum Dis       Date:  2013-06-03       Impact factor: 2.454

Review 3.  Is the CVI an acceptable indicator of content validity? Appraisal and recommendations.

Authors:  Denise F Polit; Cheryl Tatano Beck; Steven V Owen
Journal:  Res Nurs Health       Date:  2007-08       Impact factor: 2.228

4.  FACE-Q scales for health-related quality of life, early life impact, satisfaction with outcomes, and decision to have treatment: development and validation.

Authors:  Anne F Klassen; Stefan J Cano; Jonathan A Schwitzer; Amie M Scott; Andrea L Pusic
Journal:  Plast Reconstr Surg       Date:  2015-02       Impact factor: 4.730

5.  The measurement of observer agreement for categorical data.

Authors:  J R Landis; G G Koch
Journal:  Biometrics       Date:  1977-03       Impact factor: 2.571

6.  The epidemiology of morphea (localized scleroderma) in Olmsted County 1960-1993.

Authors:  L S Peterson; A M Nelson; W P Su; T Mason; W M O'Fallon; S E Gabriel
Journal:  J Rheumatol       Date:  1997-01       Impact factor: 4.666

Review 7.  Classification of morphea (localized scleroderma)

Authors:  L S Peterson; A M Nelson; W P Su
Journal:  Mayo Clin Proc       Date:  1995-11       Impact factor: 7.616

8.  Localized scleroderma severity index and global assessments: a pilot study of outcome instruments.

Authors:  Thaschawee Arkachaisri; Sally Pino
Journal:  J Rheumatol       Date:  2008-03-01       Impact factor: 4.666

Review 9.  Localized scleroderma: clinical spectrum and therapeutic update.

Authors:  Mariana Figueiroa Careta; Ricardo Romiti
Journal:  An Bras Dermatol       Date:  2015 Jan-Feb       Impact factor: 1.896

10.  Surgical Management of Localized Scleroderma.

Authors:  Jae Hyun Lee; Soo Yeon Lim; Jang Hyun Lee; Hee Chang Ahn
Journal:  Arch Craniofac Surg       Date:  2017-09-26
View more
  1 in total

1.  Association Between Fat Graft Retention and Blood Flow in Localized Scleroderma Patients: A Pilot Study.

Authors:  Hayson Chenyu Wang; Yunzhu Li; Zhujun Li; Liquan Wang; Ziming Li; Xiao Long
Journal:  Front Med (Lausanne)       Date:  2022-06-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.